# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Andrew Fein reiterates DBV Technologies (NASDAQ:DBVT) with a Buy and maintains $5 price target.
JMP Securities analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperform and raises the pr...
The Company intends to seek additional capital as it continues research and development efforts and prepares for the launch of ...
DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0....
DBV Technologies, a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunolo...
DBV Technologies Announces Plan to Implement ADS Ratio ChangeDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stoc...